No source study found
Story checked
Some People Taking Ozempic-Like Drugs Are Reporting Their Fingernails Detaching : ScienceAlert (opens in a new tab)
sciencealert.com · 2026-10-09
Short answer
No source study foundNo clear answer.
We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Some People Taking Ozempic-Like Drugs Are Reporting Their Fingernails Detaching : ScienceAlert
sciencealert.com · 2026-10-09
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We couldn't find the study behind this story.
We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.
Open claim evidenceSearch result
No source study found.
We couldn't match the article's details against the peer-reviewed literature closely enough. The study may be paywalled, very new, or not indexed.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 9Not checkedA new study asked whether nail problems were more common among people taking GLP-1 drugs used to treat obesity and type 2 diabetes.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 9Not checkedIn the study of 1,904 people across four countries, nail detachment was reported by 39% of GLP-1 users compared with 9% of people with type 2 diabetes or obesity who had never taken the drugs.View evidenceHide evidence
As stated39% vs 9%; 1,904 people across four countries
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 9Not checkedAround half of the drug users reported nail problems before treatment began.View evidenceHide evidence
As statedaround half
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 9Not checkedThe findings were presented at the European Academy of Dermatology and Venereology Congress 2026 in Vienna, and the article says the release cites conference presentations rather than a published paper.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 9Not checkedResearchers said the study showed a clear association, but they cautioned that not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 9Not checkedThe study relied on participant-reported symptoms in a cross-sectional design, so it cannot establish that the medications caused the nail changes.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 9Not checkedAfter accounting for dermatological conditions and nutritional deficiencies, nail detachment and discoloration reportedly remained about two to three times more frequent among GLP-1 users, although the exact adjusted estimates were not provided.View evidenceHide evidence
As statedabout two to three times more frequent
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 9Not checkedA companion study in the same participants reported hair and scalp symptoms, including unusual hair loss in 50% of users versus 34% of controls, but the article says this does not independently replicate the nail findings.View evidenceHide evidence
As stated50% vs 34%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 9 of 9Not checkedThe article says the release does not identify which GLP-1 drugs participants took or provide results for any specific drug, so it cannot establish a nail effect tied to any one medication.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease.
The Journal of Clinical Psychiatry · 2026 · PubMed
Advancements in GLP-1 Receptor Agonists for Treating Eating Disorders - Advancements in GLP-1 Receptor Agonists for Treating Eating Disorders: Mechanisms, Clinical Successes, Genetic Insights, and Broader Economic and Public Health Impacts
2025 · Crossref
Are GLP-1 Receptor Agonists the Missing Therapy in Vascular Risk Reduction?
JACC. Case Reports · 2026 · PubMed
Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists
Glucolipid Metabolic Disorders · 2026 · Crossref
Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632).
Ophthalmology. Retina · 2026 · PubMed
And 10 more candidates considered.